INSM — Insmed Incorporated
Healthcare • Medical - Pharmaceuticals
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung...…
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Price
Showing 5Y history. Source: FMP historical price full.
- Prev Close
- $198.46
- Day High
- $172.31
- Day Low
- $161.51
- 52w High
- $212.75
- 52w Low
- $60.40
- Volume
- 9,021,786
- Avg Volume
- Beta
- 1.017
* TTM/most recent where available
Company
- Ticker
- INSM
- Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Country
- US
- CEO
- William H. Lewis
- Employees
- 1271
- Website
- www.insmed.com
Key Metrics
- Market Cap
- 35B
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).